Investor updates Keyword Search Clear 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Published on: 21 December 2012 Roche and PSS sign agreement to develop a fully automated workflow solution for next-generation sequencing platforms Roche and Precision System Science, Co., Ltd today announced the signing of an exclusive agreement to develop and manufacture a fully automated emulsion PCR instrument for Roche’s portfolio of ... more Published on: 20 December 2012 Roche's vismodegib named Drug Discovery of the Year by the British Pharmacological Society Roche today announced that the first in class Hedgehog pathway inhibitor vismodegib, was named Drug Discovery of the Year by the British Pharmacological Society. The award, which celebrates the ... more Published on: 14 December 2012 Roche's breast cancer treatment Perjeta receives recommendation for approval in EU Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for the use of Perjeta (pertuzumab) in combination with Herceptin ... more Published on: 11 December 2012 Promising data presented at ASH support continued development of multiple investigational medicines and demonstrate breadth of Roche's robust hematology pipeline Roche announced encouraging data from four investigational medicines at the 2012 American Society of Hematology (ASH) Annual Meeting in Atlanta where over 500 abstracts related to Roche compounds ... more Published on: 8 December 2012 Roche reports positive studies of MabThera given by subcutaneous injection Pivotal study data presented at ASH shows that subcutaneous administration enables the delivery of MabThera over approximately 5 minutes without compromising MabThera’s proven efficacy and safety more Published on: 8 December 2012 Roche's Perjeta significantly extends survival in people with HER2-positive metastatic breast cancer Roche today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy ... more Published on: 7 December 2012 Changes in Roche Board of Directors At its December meeting, the Board of Directors (BoD) of Roche Holding recommended proposals for approval by the AGM, scheduled for 5 March 2013. Prof. Dr. Bruno Gehrig (born 1946, Member of the ... more Published on: 29 November 2012 Roche's Zelboraf named Best New Drug at the 2012 Scrip Awards Roche announced today that its cancer drug Zelboraf (vemurafenib) won the Best New Drug award at the 2012 Scrip Awards ceremony held in London last night. more Published on: 17 November 2012 Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening when added to radiation and chemotherapy Roche today announced results from the positive phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer ... more Published on: 16 November 2012 Roche receives positive opinion from European Medicines Agency for Avastin based treatment beyond first progression in people with advanced colorectal cancer The continued use of Avastin based therapy beyond first progression in metastatic colorectal cancer patients leads to survival benefits more Published on: 7 November 2012 FDA grants Roche's trastuzumab emtansine (T-DM1) Priority Review for HER2-positive metastatic breast cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for trastuzumab emtansine (T-DM1) and granted Priority Review. more Published on: 5 November 2012 Roche`s aleglitazar renal safety study AleNephro meets primary endpoint Roche today announced data from the Phase II AleNephro study which showed that in patients with moderate renal impairment (stage 3 chronic kidney disease) who have type 2 diabetes, the average ... more Published on: 31 October 2012 Roche medicine Avastin receives EU approval for the treatment of women with recurrent, platinum-sensitive ovarian cancer Roche announced today that the European Commission (EC) has approved Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and gemcitabine) as a treatment for women with first ... more Published on: 16 October 2012 Roche Group posts strong sales growth in the third quarter Group sales rise 4% at CER to 33.7 billion Swiss francs (+7% in Swiss francs) in the first nine months; Cancer medicines and clinical lab business drive Group performance; Perjeta launch and ... more Published on: 15 October 2012 FDA approves expanded indication for ACTEMRA in Rheumatoid Arthritis Roche today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ACTEMRA (tocilizumab) for the treatment of adults with moderately to severely active ... more Published on: 9 October 2012 Reminder: Invitation to Roche's Third Quarter Sales 2012 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2012 prior to the opening of the Swiss Stock Exchange on Tuesday, October 16th, 2012. more Published on: 5 October 2012 Anti-Cancer Agent “Avastin®,” Application for Approval of Additional Indication of Ovarian Cancer Please find attached a press release by Chugai. more Published on: 2 October 2012 Reminder - Roche conference call for investors and analysts from ESMO 2012 Tuesday, 2 October 2012, Vienna, Austria. Highlights to be discussed: T-DM1: Updated overall survival results from EMILIA, a phase 3 study of trastuzumab emtansine vs capecitabine and lapatinib in ... more Published on: 1 October 2012 Roche's trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer Roche today announced updated survival results from the Phase III EMILIA study, which showed that people with previously treated HER2-positive metastatic breast cancer (mBC) survived significantly ... more Published on: 1 October 2012 Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancer Roche and the Breast International Group (BIG) today announced final results from the Phase III HERA trial, which confirmed that one year of Herceptin(trastuzumab) treatment remains the standard of ... more Published on: 24 September 2012 ESMO 2012: Roche underscores leadership in oncology with new data in HER2 positive breast cancer and skin cancer Roche today announced that data on thirteen of its investigational and approved products will be presented at the European Society for Medical Oncology (ESMO) Congress taking place in Vienna, Austria ... more Published on: 21 September 2012 Roche's Avastin receives positive opinion from EU authority for the treatment of women with recurrent, platinum-sensitive ovarian cancer Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Avastin (bevacizumab) in combination with chemotherapy (carboplatin ... more Published on: 21 September 2012 Roche conference call for investors and analysts from ESMO 2012 We kindly invite investors and analysts to participate in a conference call that will be held during the ESMO congress from 28 September – 2 October 2012 in Vienna. more Published on: 19 September 2012 Anti-Cancer Agent “Avastin®,” Application for Approval of Additional Indication of Recurrent Glioblastoma Dear Investor, please find attached a press release by Chugai. more Published on: 18 September 2012 Invitation to Roche's Third Quarter Sales 2012 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2012 prior to the opening of the Swiss Stock Exchange on Tuesday, October 16th, 2012. more Published on: 13 September 2012 Roche leads healthcare sector in key sustainability index for fourth consecutive year Roche announced today that it has been recognised as the most sustainable healthcare company globally in the Dow Jones Sustainability Index (DJSI), for the fourth year in a row. The DJSI World and ... more Published on: 5 September 2012 Roche committed to innovation and growth Personalised healthcare leadership and world-class pipeline presented at investor conference more Published on: 28 August 2012 Changes to the Roche Corporate Executive Committee Roche announced today that Daniel O’Day, currently Chief Operating Officer (COO) of Roche Diagnostics has been appointed as COO of Roche Pharma effective September 1, 2012. He will succeed Pascal ... more Published on: 27 August 2012 New data from Phase III EMILIA study showed Roche's trastuzumab emtansine (T-DM1) significantly improved survival of people with HER2-positive metastatic breast cancer Pivotal study met co-primary efficacy endpoint of overall survival. Roche today announced updated results from the Phase III EMILIA study, which showed that trastuzumab emtansine (T-DM1) ... more Published on: 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema Roche today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with ... more Published on: 10 August 2012 Roche study showed that adding Avastin to radiation and chemotherapy significantly extended the time people with an aggressive form of brain cancer lived without their disease worsening The Phase III AVAglio study met its co-primary endpoint of significantly improving progression-free survival in people with glioblastoma. Roche announced today that the phase III AVAglio study of ... more Published on: 27 July 2012 FDA advisory committee unanimously recommends approval of Lucentis for treatment of diabetic macular edema (DME) Roche announced that the U.S. Food & Drug Administration (FDA) Dermatologic & Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (10-0) to recommend approval of the 0.3 mg dose of Lucentis ... more Published on: 27 July 2012 Roche reports second positive study of RoACTEMRA given by subcutaneous injection to patients with rheumatoid arthritis Roche today announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its ... more Published on: 26 July 2012 Full reconciliation of Chugai half-year 2012 results into IFRS Results of Chugai as consolidated by the Roche Group more Published on: 26 July 2012 FDA clears Roche's vitamin D laboratory test Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for a fully automated vitamin D test for use on cobas modular platforms, further expanding the ... more Published on: 26 July 2012 Roche posts strong operating first-half results; on track to meet 2012 guidance Roche posts strong operating first-half results; on track to meet 2012 guidance more Published on: 19 July 2012 Reminder: Invitation to Roche's Half Year Results for 2012 Roche will publish its Half Year Results for 2012 prior to the opening of the Swiss Stock Exchange on 26th July, 2012 more Published on: 19 July 2012 FDA clears Accu-Chek Combo system - Roche's new interactive insulin pump system for people with diabetes The system will be available in the United States in the second half of 2012. Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Accu-Chek ... more Published on: 27 June 2012 Invitation to Roche's Half Year Results for 2012 Roche will publish its Half Year Results for 2012 prior to the opening of the Swiss Stock Exchange on 26th July, 2012. more Published on: 26 June 2012 Roche to streamline research and development activities Roche site in Nutley (New Jersey, USA) to be closed – respective R&D activities to be consolidated in Switzerland and Germany. The planned site consolidation and the streamlining of research ... more Published on: 26 June 2012 Anti-Cancer Agent “Tarceva®”, Application for Approval of Additional Indication of Non-Small Cell Lung Cancer (First Line Therapy) Please find attached a press release by Chugai more Published on: 22 June 2012 New data from Phase III study showed that people with HER2-positive metastatic breast cancer lived longer with Roche's Perjeta Roche announced today that people with HER-2 positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin ... more Published on: 19 June 2012 Roche and Seaside Therapeutics Announce Landmark Alliance to Advance Novel Treatments for Fragile X Syndrome and Autism Spectrum Disorders Roche and Seaside Therapeutics announced today that they have entered into a collaboration to develop disease modifying treatments for fragile X syndrome (FXS) and autism spectrum disorders (ASD), ... more Published on: 11 June 2012 FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer New personalised medicine gives people with aggressive form of breast cancer more time without their disease worsening. Roche today announced that the U.S. Food and Drug Administration (FDA) has ... more Published on: 6 June 2012 Roche's RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche today announced data from the ADACTA study which showed that adult rheumatoid arthritis (RA) patients who received RoACTEMRA (tocilizumab) as single-agent therapy (without other DMARDs) ... more Published on: 3 June 2012 Roche's targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III trial Roche today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint, of a significant improvement in the time patients with HER2-positive metastatic ... more Published on: 3 June 2012 Roche data showed that people with metastatic colorectal cancer lived longer when they continued on Avastin plus chemotherapy Roche today announced results from ML18147, a phase III study in metastatic colorectal cancer (mCRC) that evaluated Avastin (bevacizumab) continued with second-line chemotherapy in people who ... more Published on: 2 June 2012 Roche study showed that adding Avastin to chemotherapy cut the risk of the disease getting worse in difficult-to-treat recurrent ovarian cancer by half Roche today announced results from AURELIA, a phase III study that evaluated treatment with Avastin (bevacizumab) in combination with standard chemotherapy (weekly paclitaxel, topotecan or pegylated ... more Published on: 1 June 2012 Reminder: Roche conference call for investors and analysts from EULAR 2012 ADACTA, a phase IV study evaluating the reduction in rheumatoid arthritis disease activity during monotherapy treatment with Actemra compared to adalimumab more Published on: 30 May 2012 Reminder: Roche Analyst Event at ASCO 2012 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more Published on: 25 May 2012 Roche Analyst Event at ASCO 2012 Analyst briefing on data presented at ASCO: Sunday, 3rd June 2012 more Published on: 25 May 2012 New Drug Application Filed for Anti-Cancer Agent “Pertuzumab” for the Treatment of HER2-Positive Metastatic or Recurrent Breast Cancer Please find attached a press release by Chugai more Published on: 24 May 2012 Invitation Roche Investor Day 2012 Dr Severin Schwan (CEO Roche group) and the Investor Relations team would like to invite you to the Roche Investor Day to be held on Wednesday, 5th September 2012 in London. more Published on: 16 May 2012 Roche will report new data on important progress for people with advanced cancers at ASCO 2012 Roche today announced that the company will present important new data from studies of several of its cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), ... more Published on: 10 May 2012 Roche conference call for investors and analysts from EULAR 2012 ADACTA, a phase IV study evaluating the reduction in rheumatoid arthritis disease activity during monotherapy treatment with Actemra compared to adalimumab - Friday, 8 June 2012, Berlin, Germany. We ... more Published on: 7 May 2012 Roche provides update on Phase III study of dalcetrapib Roche today announced that following the results of the second interim analysis of the dalcetrapib dal-OUTCOMES Phase III trial, the independent Data and Safety Monitoring Board (DSMB) has ... more Published on: 3 May 2012 Roche Analyst Event at ASCO 2012 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more Published on: 3 May 2012 Roche reports positive study of RoACTEMRA given by subcutaneous injection Roche today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) formulation of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) ... more Published on: 19 April 2012 Roche reports high rates of sustained viral clearance with investigational hepatitis C treatment danoprevir Roche today announced data showing high SVR12 rates (maintaining undetectable viral levels 12 weeks after stopping treatment) and good tolerability with its second generation protease inhibitor ... more Published on: 18 April 2012 Roche decides not to extend its tender offer for Illumina, Inc. Roche released the following statement based on preliminary estimates indicating the re-election of the incumbent directors of Illumina, Inc. (NASDAQ: ILMN) at the Illumina annual meeting more Published on: 12 April 2012 Roche on track for full-year targets – good sales growth in first quarter Group sales rise 2% at CER (-1% in Swiss francs; +1% in US dollars) to 11.0 billion Swiss francs. Excluding Tamiflu, sales growth is 3%. more Published on: 12 April 2012 Roche issues statement regarding Illumina offer Roche released the following statement regarding its pending offer for Illumina, Inc. (NASDAQ: ILMN) more Published on: 11 April 2012 Roche sends open letter to Illumina shareholders Roche today sent an open letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to vote the GOLD proxy card for Roche’s independent director nominees and other proposals at the 2012 ... more Published on: 6 April 2012 Roche disappointed with ISS recommendation Roche released the following statement in response to a report issued by Institutional Shareholder Services (“ISS”) recommending that shareholders of Illumina, Inc. (NASDAQ: ILMN) vote against the ... more Published on: 4 April 2012 Roche sends second letter to Illumina shareholders Roche (SIX: RO, ROG; OTCQX: RHHBY) today sent a second letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to tender their shares into Roche’s increased offer and vote for Roche’s ... more Published on: 3 April 2012 Reminder: Invitation to Roche's First Quarter Sales 2012 Conference Call Roche will publish its Sales Results for the 1st Quarter of 2012 prior to the opening of the Swiss Stock Exchange on Thursday 12th April, 2012. more Published on: 3 April 2012 Roche disappointed by Illumina, Inc.'s Board of Directors' rejection By not engaging with Roche, Illumina reinforces notion of an entrenched Board. Roche released the following statement in response to the announcement by Illumina, Inc. (NASDAQ: ILMN) that its Board ... more Published on: 30 March 2012 Roche's trastuzumab emtansine (T-DM1) showed positive Phase III results in HER2-positive metastatic breast cancer Roche today announced topline results of EMILIA, the first randomised Phase III study of trastuzumab emtansine (T-DM1). more Published on: 29 March 2012 Roche increases offer price for Illumina shares to US$ 51.00 per share Roche announced today that it has increased its offer price for all outstanding publicly-held shares of Illumina, Inc. (NASDAQ: ILMN) to US$ 51.00 per share in cash. All other terms and conditions of ... more Published on: 26 March 2012 Roche extends tender offer for Illumina Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ILMN), at a price of $44.50 per share, to 6:00 p.m., New York City time, ... more Published on: 23 March 2012 Roche's Herceptin given by subcutaneous injection offers greater convenience to patients and reduces overall healthcare costs compared to standard IV infusion Subcutaneous administration of Herceptin is less invasive and takes approximately 5 minutes instead of 30-90 minutes with currently approved IV administration. more Published on: 20 March 2012 Roche files definitive proxy statement Roche today announced that it filed its definitive proxy statement and sent a letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to tender their shares into Roche’s offer and vote ... more Published on: 13 March 2012 Roche receives request for additional information from the Federal Trade Commission Roche announced today that it has received a request for additional information, often referred to as a “second request,” from the Federal Trade Commission (“FTC”) in connection with Roche’s proposed ... more Published on: 12 March 2012 Invitation to Roche's First Quarter Sales 2012 Conference Call Roche will publish its Sales Results for the 1st Quarter of 2012 prior to the opening of the Swiss Stock Exchange on Thursday 12th April, 2012. more Published on: 12 March 2012 Second Transnet-Phelophepa Healthcare Train inaugurated in South Africa Roche doubles its support for unique project providing healthcare to reach 90,000 patients a year in rural South Africa. Today, Transnet Foundation and Roche inaugurated a second Phelophepa ... more Published on: 6 March 2012 Roche Annual General Meeting 2012 Roche's Annual General Meeting, held today in Basel, approved all of the Board of Directors' proposals. The 755 shareholders in attendance, representing 87.4% of a total of 160,000,000 bearer shares, ... more Published on: 2 March 2012 Roche's RoACTEMRA monotherapy showed superior improvement in rheumatoid arthritis signs and symptoms versus adalimumab monotherapy Roche today announced that preliminary results from the ADACTA study (ADalimumab ACTemrA) showed that patients who received RoACTEMRA (tocilizumab) as monotherapy achieved a significantly greater ... more Published on: 27 February 2012 Roche extends tender offer for Illumina Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ILMN), at a price of $44.50 per share, to 6:00 p.m., New York City time, ... more Published on: 20 February 2012 Roche's Zelboraf receives EU approval for the treatment of people with deadly form of skin cancer First and only personalized skin cancer medicine allows people with BRAF V600 mutation-positive metastatic melanoma to live significantly longer. Roche today announced that the European Commission ... more Published on: 8 February 2012 FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application for pertuzumab and granted Priority Review. more Published on: 8 February 2012 Roche disappointed by the actions of Illumina, Inc.'s Board of Directors Roche released the following statement in response to the announcement by Illumina, Inc. that its Board of Directors has recommended that shareholders not tender their shares to Roche. more Published on: 1 February 2012 Full reconciliation of Chugai 2011 results into IFRS Following the publication of Chugai’s official 2011 results, Roche offers this investor update which reconciles these results with the results for Chugai published by Roche as part of the Roche ... more Published on: 1 February 2012 Roche in 2011: Strong results and positive outlook Group sales rise 2% 1 (-10% in Swiss francs; +6% in US dollars), excluding Tamiflu; Significant foreign exchange impact of –12 percentage points due to appreciation of the Swiss franc; overall Group ... more Published on: 31 January 2012 Roche to nominate slate of independent directors for election at Illumina, Inc.'s 2012 annual meeting Roche announced today that it has provided notice to Illumina, Inc. (NASDAQ: ILMN) that it will nominate a slate of highly qualified, independent candidates for election to Illumina’s Board of ... more Published on: 30 January 2012 FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma Roche today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for adults with a type of skin cancer, called basal cell carcinoma (BCC), that has ... more Published on: 27 January 2012 Roche commences tender offer for Illumina, Inc. for $44.50 per share in cash Roche, a leader in research-focused healthcare with combined strengths in pharmaceuticals, life science tools and diagnostics, announced today that it has commenced a cash tender offer to acquire all ... more Published on: 27 January 2012 Roche responds to adoption of shareholder rights plan by Illumina Board of Directors Roche today responded to an announcement from Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has adopted a shareholder rights plan. more Published on: 26 January 2012 Avastin-based regimen extends survival when continued beyond initial treatment in patients with metastatic colorectal cancer First randomised phase III trial evaluating continued use of Avastin with chemotherapy after disease progression meets primary endpoint. Roche announced today that a phase III study (ML 18147) in ... more Published on: 25 January 2012 Roche offers to acquire all outstanding shares of Illumina, Inc. to further strengthen its leading role in diagnostics Roche announced today that it is proposing to acquire all outstanding shares of Illumina, Inc. (NASDAQ:ILMN) for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully ... more Published on: 18 January 2012 Reminder: Invitation to Roche's Full Year Results for 2011 Roche will publish its Full Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 1st February 2012 at 7:00 CET / 6:00 GMT / 1:00 AM EST / 10:00PM PST (evening before) more Published on: 11 January 2012 Roche receives clearance from the U.S. Food and Drug Administration for the new Accu-Chek Nano SmartView blood glucose monitoring system Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Nano SmartView blood glucose monitoring system. The new Accu-Chek Nano meter, ... more Published on: 3 January 2012 Invitation to Roche's Full Year Results for 2011 Roche will publish its Full Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 1st February 2012 at 7:00 CET / 6:00 GMT / 1:00 AM EST / 10:00PM PST (evening before) more
Published on: 21 December 2012 Roche and PSS sign agreement to develop a fully automated workflow solution for next-generation sequencing platforms Roche and Precision System Science, Co., Ltd today announced the signing of an exclusive agreement to develop and manufacture a fully automated emulsion PCR instrument for Roche’s portfolio of ... more
Published on: 20 December 2012 Roche's vismodegib named Drug Discovery of the Year by the British Pharmacological Society Roche today announced that the first in class Hedgehog pathway inhibitor vismodegib, was named Drug Discovery of the Year by the British Pharmacological Society. The award, which celebrates the ... more
Published on: 14 December 2012 Roche's breast cancer treatment Perjeta receives recommendation for approval in EU Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for the use of Perjeta (pertuzumab) in combination with Herceptin ... more
Published on: 11 December 2012 Promising data presented at ASH support continued development of multiple investigational medicines and demonstrate breadth of Roche's robust hematology pipeline Roche announced encouraging data from four investigational medicines at the 2012 American Society of Hematology (ASH) Annual Meeting in Atlanta where over 500 abstracts related to Roche compounds ... more
Published on: 8 December 2012 Roche reports positive studies of MabThera given by subcutaneous injection Pivotal study data presented at ASH shows that subcutaneous administration enables the delivery of MabThera over approximately 5 minutes without compromising MabThera’s proven efficacy and safety more
Published on: 8 December 2012 Roche's Perjeta significantly extends survival in people with HER2-positive metastatic breast cancer Roche today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy ... more
Published on: 7 December 2012 Changes in Roche Board of Directors At its December meeting, the Board of Directors (BoD) of Roche Holding recommended proposals for approval by the AGM, scheduled for 5 March 2013. Prof. Dr. Bruno Gehrig (born 1946, Member of the ... more
Published on: 29 November 2012 Roche's Zelboraf named Best New Drug at the 2012 Scrip Awards Roche announced today that its cancer drug Zelboraf (vemurafenib) won the Best New Drug award at the 2012 Scrip Awards ceremony held in London last night. more
Published on: 17 November 2012 Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening when added to radiation and chemotherapy Roche today announced results from the positive phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer ... more
Published on: 16 November 2012 Roche receives positive opinion from European Medicines Agency for Avastin based treatment beyond first progression in people with advanced colorectal cancer The continued use of Avastin based therapy beyond first progression in metastatic colorectal cancer patients leads to survival benefits more
Published on: 7 November 2012 FDA grants Roche's trastuzumab emtansine (T-DM1) Priority Review for HER2-positive metastatic breast cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for trastuzumab emtansine (T-DM1) and granted Priority Review. more
Published on: 5 November 2012 Roche`s aleglitazar renal safety study AleNephro meets primary endpoint Roche today announced data from the Phase II AleNephro study which showed that in patients with moderate renal impairment (stage 3 chronic kidney disease) who have type 2 diabetes, the average ... more
Published on: 31 October 2012 Roche medicine Avastin receives EU approval for the treatment of women with recurrent, platinum-sensitive ovarian cancer Roche announced today that the European Commission (EC) has approved Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and gemcitabine) as a treatment for women with first ... more
Published on: 16 October 2012 Roche Group posts strong sales growth in the third quarter Group sales rise 4% at CER to 33.7 billion Swiss francs (+7% in Swiss francs) in the first nine months; Cancer medicines and clinical lab business drive Group performance; Perjeta launch and ... more
Published on: 15 October 2012 FDA approves expanded indication for ACTEMRA in Rheumatoid Arthritis Roche today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ACTEMRA (tocilizumab) for the treatment of adults with moderately to severely active ... more
Published on: 9 October 2012 Reminder: Invitation to Roche's Third Quarter Sales 2012 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2012 prior to the opening of the Swiss Stock Exchange on Tuesday, October 16th, 2012. more
Published on: 5 October 2012 Anti-Cancer Agent “Avastin®,” Application for Approval of Additional Indication of Ovarian Cancer Please find attached a press release by Chugai. more
Published on: 2 October 2012 Reminder - Roche conference call for investors and analysts from ESMO 2012 Tuesday, 2 October 2012, Vienna, Austria. Highlights to be discussed: T-DM1: Updated overall survival results from EMILIA, a phase 3 study of trastuzumab emtansine vs capecitabine and lapatinib in ... more
Published on: 1 October 2012 Roche's trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer Roche today announced updated survival results from the Phase III EMILIA study, which showed that people with previously treated HER2-positive metastatic breast cancer (mBC) survived significantly ... more
Published on: 1 October 2012 Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancer Roche and the Breast International Group (BIG) today announced final results from the Phase III HERA trial, which confirmed that one year of Herceptin(trastuzumab) treatment remains the standard of ... more
Published on: 24 September 2012 ESMO 2012: Roche underscores leadership in oncology with new data in HER2 positive breast cancer and skin cancer Roche today announced that data on thirteen of its investigational and approved products will be presented at the European Society for Medical Oncology (ESMO) Congress taking place in Vienna, Austria ... more
Published on: 21 September 2012 Roche's Avastin receives positive opinion from EU authority for the treatment of women with recurrent, platinum-sensitive ovarian cancer Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Avastin (bevacizumab) in combination with chemotherapy (carboplatin ... more
Published on: 21 September 2012 Roche conference call for investors and analysts from ESMO 2012 We kindly invite investors and analysts to participate in a conference call that will be held during the ESMO congress from 28 September – 2 October 2012 in Vienna. more
Published on: 19 September 2012 Anti-Cancer Agent “Avastin®,” Application for Approval of Additional Indication of Recurrent Glioblastoma Dear Investor, please find attached a press release by Chugai. more
Published on: 18 September 2012 Invitation to Roche's Third Quarter Sales 2012 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2012 prior to the opening of the Swiss Stock Exchange on Tuesday, October 16th, 2012. more
Published on: 13 September 2012 Roche leads healthcare sector in key sustainability index for fourth consecutive year Roche announced today that it has been recognised as the most sustainable healthcare company globally in the Dow Jones Sustainability Index (DJSI), for the fourth year in a row. The DJSI World and ... more
Published on: 5 September 2012 Roche committed to innovation and growth Personalised healthcare leadership and world-class pipeline presented at investor conference more
Published on: 28 August 2012 Changes to the Roche Corporate Executive Committee Roche announced today that Daniel O’Day, currently Chief Operating Officer (COO) of Roche Diagnostics has been appointed as COO of Roche Pharma effective September 1, 2012. He will succeed Pascal ... more
Published on: 27 August 2012 New data from Phase III EMILIA study showed Roche's trastuzumab emtansine (T-DM1) significantly improved survival of people with HER2-positive metastatic breast cancer Pivotal study met co-primary efficacy endpoint of overall survival. Roche today announced updated results from the Phase III EMILIA study, which showed that trastuzumab emtansine (T-DM1) ... more
Published on: 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema Roche today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with ... more
Published on: 10 August 2012 Roche study showed that adding Avastin to radiation and chemotherapy significantly extended the time people with an aggressive form of brain cancer lived without their disease worsening The Phase III AVAglio study met its co-primary endpoint of significantly improving progression-free survival in people with glioblastoma. Roche announced today that the phase III AVAglio study of ... more
Published on: 27 July 2012 FDA advisory committee unanimously recommends approval of Lucentis for treatment of diabetic macular edema (DME) Roche announced that the U.S. Food & Drug Administration (FDA) Dermatologic & Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (10-0) to recommend approval of the 0.3 mg dose of Lucentis ... more
Published on: 27 July 2012 Roche reports second positive study of RoACTEMRA given by subcutaneous injection to patients with rheumatoid arthritis Roche today announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its ... more
Published on: 26 July 2012 Full reconciliation of Chugai half-year 2012 results into IFRS Results of Chugai as consolidated by the Roche Group more
Published on: 26 July 2012 FDA clears Roche's vitamin D laboratory test Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for a fully automated vitamin D test for use on cobas modular platforms, further expanding the ... more
Published on: 26 July 2012 Roche posts strong operating first-half results; on track to meet 2012 guidance Roche posts strong operating first-half results; on track to meet 2012 guidance more
Published on: 19 July 2012 Reminder: Invitation to Roche's Half Year Results for 2012 Roche will publish its Half Year Results for 2012 prior to the opening of the Swiss Stock Exchange on 26th July, 2012 more
Published on: 19 July 2012 FDA clears Accu-Chek Combo system - Roche's new interactive insulin pump system for people with diabetes The system will be available in the United States in the second half of 2012. Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Accu-Chek ... more
Published on: 27 June 2012 Invitation to Roche's Half Year Results for 2012 Roche will publish its Half Year Results for 2012 prior to the opening of the Swiss Stock Exchange on 26th July, 2012. more
Published on: 26 June 2012 Roche to streamline research and development activities Roche site in Nutley (New Jersey, USA) to be closed – respective R&D activities to be consolidated in Switzerland and Germany. The planned site consolidation and the streamlining of research ... more
Published on: 26 June 2012 Anti-Cancer Agent “Tarceva®”, Application for Approval of Additional Indication of Non-Small Cell Lung Cancer (First Line Therapy) Please find attached a press release by Chugai more
Published on: 22 June 2012 New data from Phase III study showed that people with HER2-positive metastatic breast cancer lived longer with Roche's Perjeta Roche announced today that people with HER-2 positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin ... more
Published on: 19 June 2012 Roche and Seaside Therapeutics Announce Landmark Alliance to Advance Novel Treatments for Fragile X Syndrome and Autism Spectrum Disorders Roche and Seaside Therapeutics announced today that they have entered into a collaboration to develop disease modifying treatments for fragile X syndrome (FXS) and autism spectrum disorders (ASD), ... more
Published on: 11 June 2012 FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer New personalised medicine gives people with aggressive form of breast cancer more time without their disease worsening. Roche today announced that the U.S. Food and Drug Administration (FDA) has ... more
Published on: 6 June 2012 Roche's RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche today announced data from the ADACTA study which showed that adult rheumatoid arthritis (RA) patients who received RoACTEMRA (tocilizumab) as single-agent therapy (without other DMARDs) ... more
Published on: 3 June 2012 Roche's targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III trial Roche today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint, of a significant improvement in the time patients with HER2-positive metastatic ... more
Published on: 3 June 2012 Roche data showed that people with metastatic colorectal cancer lived longer when they continued on Avastin plus chemotherapy Roche today announced results from ML18147, a phase III study in metastatic colorectal cancer (mCRC) that evaluated Avastin (bevacizumab) continued with second-line chemotherapy in people who ... more
Published on: 2 June 2012 Roche study showed that adding Avastin to chemotherapy cut the risk of the disease getting worse in difficult-to-treat recurrent ovarian cancer by half Roche today announced results from AURELIA, a phase III study that evaluated treatment with Avastin (bevacizumab) in combination with standard chemotherapy (weekly paclitaxel, topotecan or pegylated ... more
Published on: 1 June 2012 Reminder: Roche conference call for investors and analysts from EULAR 2012 ADACTA, a phase IV study evaluating the reduction in rheumatoid arthritis disease activity during monotherapy treatment with Actemra compared to adalimumab more
Published on: 30 May 2012 Reminder: Roche Analyst Event at ASCO 2012 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more
Published on: 25 May 2012 Roche Analyst Event at ASCO 2012 Analyst briefing on data presented at ASCO: Sunday, 3rd June 2012 more
Published on: 25 May 2012 New Drug Application Filed for Anti-Cancer Agent “Pertuzumab” for the Treatment of HER2-Positive Metastatic or Recurrent Breast Cancer Please find attached a press release by Chugai more
Published on: 24 May 2012 Invitation Roche Investor Day 2012 Dr Severin Schwan (CEO Roche group) and the Investor Relations team would like to invite you to the Roche Investor Day to be held on Wednesday, 5th September 2012 in London. more
Published on: 16 May 2012 Roche will report new data on important progress for people with advanced cancers at ASCO 2012 Roche today announced that the company will present important new data from studies of several of its cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), ... more
Published on: 10 May 2012 Roche conference call for investors and analysts from EULAR 2012 ADACTA, a phase IV study evaluating the reduction in rheumatoid arthritis disease activity during monotherapy treatment with Actemra compared to adalimumab - Friday, 8 June 2012, Berlin, Germany. We ... more
Published on: 7 May 2012 Roche provides update on Phase III study of dalcetrapib Roche today announced that following the results of the second interim analysis of the dalcetrapib dal-OUTCOMES Phase III trial, the independent Data and Safety Monitoring Board (DSMB) has ... more
Published on: 3 May 2012 Roche Analyst Event at ASCO 2012 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more
Published on: 3 May 2012 Roche reports positive study of RoACTEMRA given by subcutaneous injection Roche today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) formulation of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) ... more
Published on: 19 April 2012 Roche reports high rates of sustained viral clearance with investigational hepatitis C treatment danoprevir Roche today announced data showing high SVR12 rates (maintaining undetectable viral levels 12 weeks after stopping treatment) and good tolerability with its second generation protease inhibitor ... more
Published on: 18 April 2012 Roche decides not to extend its tender offer for Illumina, Inc. Roche released the following statement based on preliminary estimates indicating the re-election of the incumbent directors of Illumina, Inc. (NASDAQ: ILMN) at the Illumina annual meeting more
Published on: 12 April 2012 Roche on track for full-year targets – good sales growth in first quarter Group sales rise 2% at CER (-1% in Swiss francs; +1% in US dollars) to 11.0 billion Swiss francs. Excluding Tamiflu, sales growth is 3%. more
Published on: 12 April 2012 Roche issues statement regarding Illumina offer Roche released the following statement regarding its pending offer for Illumina, Inc. (NASDAQ: ILMN) more
Published on: 11 April 2012 Roche sends open letter to Illumina shareholders Roche today sent an open letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to vote the GOLD proxy card for Roche’s independent director nominees and other proposals at the 2012 ... more
Published on: 6 April 2012 Roche disappointed with ISS recommendation Roche released the following statement in response to a report issued by Institutional Shareholder Services (“ISS”) recommending that shareholders of Illumina, Inc. (NASDAQ: ILMN) vote against the ... more
Published on: 4 April 2012 Roche sends second letter to Illumina shareholders Roche (SIX: RO, ROG; OTCQX: RHHBY) today sent a second letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to tender their shares into Roche’s increased offer and vote for Roche’s ... more
Published on: 3 April 2012 Reminder: Invitation to Roche's First Quarter Sales 2012 Conference Call Roche will publish its Sales Results for the 1st Quarter of 2012 prior to the opening of the Swiss Stock Exchange on Thursday 12th April, 2012. more
Published on: 3 April 2012 Roche disappointed by Illumina, Inc.'s Board of Directors' rejection By not engaging with Roche, Illumina reinforces notion of an entrenched Board. Roche released the following statement in response to the announcement by Illumina, Inc. (NASDAQ: ILMN) that its Board ... more
Published on: 30 March 2012 Roche's trastuzumab emtansine (T-DM1) showed positive Phase III results in HER2-positive metastatic breast cancer Roche today announced topline results of EMILIA, the first randomised Phase III study of trastuzumab emtansine (T-DM1). more
Published on: 29 March 2012 Roche increases offer price for Illumina shares to US$ 51.00 per share Roche announced today that it has increased its offer price for all outstanding publicly-held shares of Illumina, Inc. (NASDAQ: ILMN) to US$ 51.00 per share in cash. All other terms and conditions of ... more
Published on: 26 March 2012 Roche extends tender offer for Illumina Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ILMN), at a price of $44.50 per share, to 6:00 p.m., New York City time, ... more
Published on: 23 March 2012 Roche's Herceptin given by subcutaneous injection offers greater convenience to patients and reduces overall healthcare costs compared to standard IV infusion Subcutaneous administration of Herceptin is less invasive and takes approximately 5 minutes instead of 30-90 minutes with currently approved IV administration. more
Published on: 20 March 2012 Roche files definitive proxy statement Roche today announced that it filed its definitive proxy statement and sent a letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to tender their shares into Roche’s offer and vote ... more
Published on: 13 March 2012 Roche receives request for additional information from the Federal Trade Commission Roche announced today that it has received a request for additional information, often referred to as a “second request,” from the Federal Trade Commission (“FTC”) in connection with Roche’s proposed ... more
Published on: 12 March 2012 Invitation to Roche's First Quarter Sales 2012 Conference Call Roche will publish its Sales Results for the 1st Quarter of 2012 prior to the opening of the Swiss Stock Exchange on Thursday 12th April, 2012. more
Published on: 12 March 2012 Second Transnet-Phelophepa Healthcare Train inaugurated in South Africa Roche doubles its support for unique project providing healthcare to reach 90,000 patients a year in rural South Africa. Today, Transnet Foundation and Roche inaugurated a second Phelophepa ... more
Published on: 6 March 2012 Roche Annual General Meeting 2012 Roche's Annual General Meeting, held today in Basel, approved all of the Board of Directors' proposals. The 755 shareholders in attendance, representing 87.4% of a total of 160,000,000 bearer shares, ... more
Published on: 2 March 2012 Roche's RoACTEMRA monotherapy showed superior improvement in rheumatoid arthritis signs and symptoms versus adalimumab monotherapy Roche today announced that preliminary results from the ADACTA study (ADalimumab ACTemrA) showed that patients who received RoACTEMRA (tocilizumab) as monotherapy achieved a significantly greater ... more
Published on: 27 February 2012 Roche extends tender offer for Illumina Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ILMN), at a price of $44.50 per share, to 6:00 p.m., New York City time, ... more
Published on: 20 February 2012 Roche's Zelboraf receives EU approval for the treatment of people with deadly form of skin cancer First and only personalized skin cancer medicine allows people with BRAF V600 mutation-positive metastatic melanoma to live significantly longer. Roche today announced that the European Commission ... more
Published on: 8 February 2012 FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application for pertuzumab and granted Priority Review. more
Published on: 8 February 2012 Roche disappointed by the actions of Illumina, Inc.'s Board of Directors Roche released the following statement in response to the announcement by Illumina, Inc. that its Board of Directors has recommended that shareholders not tender their shares to Roche. more
Published on: 1 February 2012 Full reconciliation of Chugai 2011 results into IFRS Following the publication of Chugai’s official 2011 results, Roche offers this investor update which reconciles these results with the results for Chugai published by Roche as part of the Roche ... more
Published on: 1 February 2012 Roche in 2011: Strong results and positive outlook Group sales rise 2% 1 (-10% in Swiss francs; +6% in US dollars), excluding Tamiflu; Significant foreign exchange impact of –12 percentage points due to appreciation of the Swiss franc; overall Group ... more
Published on: 31 January 2012 Roche to nominate slate of independent directors for election at Illumina, Inc.'s 2012 annual meeting Roche announced today that it has provided notice to Illumina, Inc. (NASDAQ: ILMN) that it will nominate a slate of highly qualified, independent candidates for election to Illumina’s Board of ... more
Published on: 30 January 2012 FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma Roche today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for adults with a type of skin cancer, called basal cell carcinoma (BCC), that has ... more
Published on: 27 January 2012 Roche commences tender offer for Illumina, Inc. for $44.50 per share in cash Roche, a leader in research-focused healthcare with combined strengths in pharmaceuticals, life science tools and diagnostics, announced today that it has commenced a cash tender offer to acquire all ... more
Published on: 27 January 2012 Roche responds to adoption of shareholder rights plan by Illumina Board of Directors Roche today responded to an announcement from Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has adopted a shareholder rights plan. more
Published on: 26 January 2012 Avastin-based regimen extends survival when continued beyond initial treatment in patients with metastatic colorectal cancer First randomised phase III trial evaluating continued use of Avastin with chemotherapy after disease progression meets primary endpoint. Roche announced today that a phase III study (ML 18147) in ... more
Published on: 25 January 2012 Roche offers to acquire all outstanding shares of Illumina, Inc. to further strengthen its leading role in diagnostics Roche announced today that it is proposing to acquire all outstanding shares of Illumina, Inc. (NASDAQ:ILMN) for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully ... more
Published on: 18 January 2012 Reminder: Invitation to Roche's Full Year Results for 2011 Roche will publish its Full Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 1st February 2012 at 7:00 CET / 6:00 GMT / 1:00 AM EST / 10:00PM PST (evening before) more
Published on: 11 January 2012 Roche receives clearance from the U.S. Food and Drug Administration for the new Accu-Chek Nano SmartView blood glucose monitoring system Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Nano SmartView blood glucose monitoring system. The new Accu-Chek Nano meter, ... more
Published on: 3 January 2012 Invitation to Roche's Full Year Results for 2011 Roche will publish its Full Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 1st February 2012 at 7:00 CET / 6:00 GMT / 1:00 AM EST / 10:00PM PST (evening before) more